Assessment of Myocardial Fibrosis in Marfan Syndrome Using Cardiac Magnetic Resonance Imaging
Molecular Genetics & Genomic Medicine · 2024-11 · 12 (11)
DOI: 10.1002/mgg3.70024 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Genetics & Genomic Medicine, online erschienen am 15.11.2024. Verfasst von Anthony Demolder und 3 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Medical Genetics, Ghent University Hospital, Ghent, Belgium. Hauptthemen laut MEDLINE: Marfan Syndrome, Fibrosis, Myocardium. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Impaired myocardial function and arrhythmia are important manifestations of Marfan syndrome (MFS). Studies assessing myocardial fibrosis in relation to these manifestations are scarce.
Methods
This cross‐sectional, single‐center study assessed ventricular volumes, ventricular function, and myocardial fibrosis by cardiac magnetic resonance imaging (CMR) in patients with MFS harboring a (likely) pathogenic FBN1 variant. The presence and extent of fibrosis were assessed by late gadolinium enhancement (LGE) and extracellular volume measurement (ECV). Data on 24‐h Holter monitoring and clinical data were extracted from electronic patient records.
Results
The study included 32 unselected patients with MFS (median age 38 years [range 10–69], 41% women). No focal myocardial fibrosis was detected. Six patients (21%) had diffuse fibrosis (ECV > 29%). No association was found between the presence of diffuse fibrosis and clinically relevant myocardial dysfunction. Five patients (16%) had reduced left ventricular ejection fraction (LVEF < 55%). While all of these exhibited mitral annular disjunction (MAD), only two had ECV > 29%. Patients with MAD had increased indexed LV volumes (median end‐diastolic volume, 92 mL/m 2 [IQR, 78–100] vs. 78 mL/m 2 [IQR, 71–87]; median end‐systolic volume, 31 mL/m 2 [IQR, 23–46] vs. 22 mL/m 2 [IQR, 21–28]), also after adjusting for the presence of mitral and aortic valve regurgitation. No differences in ECV were seen between patients with and without MAD.
Conclusions
In this cohort of patients with MFS, focal myocardial fibrosis was not detected using CMR. Although diffuse fibrosis was observed in 21% of patients, no evident connection to clinically relevant myocardial dysfunction was found. Further studies should evaluate the impact of diffuse fibrosis on clinical outcome prediction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Medical Genetics, Ghent University Hospital, Ghent, Belgium.
- Department of Cardiology, Ghent University Hospital, Ghent, Belgium.
- Department of Radiology, Ghent University Hospital, Ghent, Belgium.
- Division of Paediatric Cardiology, Department of Paediatrics, Ghent University Hospital, Ghent, Belgium.
ORCID-Profile: Anthony Demolder, Julie De Backer, Laura Muiño-Mosquera
Zitieren
APA
Demolder, A., Devos, D., De Backer, J., & Muiño-Mosquera, L. (2024). Assessment of Myocardial Fibrosis in Marfan Syndrome Using Cardiac Magnetic Resonance Imaging. Molecular Genetics & Genomic Medicine, 12(11). https://doi.org/10.1002/mgg3.70024
Vancouver
Demolder A, Devos D, De Backer J, Muiño-Mosquera L. Assessment of Myocardial Fibrosis in Marfan Syndrome Using Cardiac Magnetic Resonance Imaging. Molecular Genetics & Genomic Medicine. 2024;12(11). doi:10.1002/mgg3.70024
BibTeX
@article{Demolder2024,
author = {Demolder, Anthony and Devos, Dan and De Backer, Julie and Muiño-Mosquera, Laura},
title = {Assessment of Myocardial Fibrosis in Marfan Syndrome Using Cardiac Magnetic Resonance Imaging},
journal = {Molecular Genetics & Genomic Medicine},
year = {2024},
volume = {12},
number = {11},
doi = {10.1002/mgg3.70024}
}
EUVIMED